Martingale Asset Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Martingale Asset Management’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,706	Closed	-$268K	–	960
2021 Q2	$268K	Buy	+9,706	New	+$191K	﹤0.01%	740
2021 Q1	–	Sell	-20,222	Closed	-$374K	–	948
2020 Q4	$374K	Sell	20,222 -72,191	-78%	-$1.29M	﹤0.01%	696
2020 Q3	$1.26M	Sell	92,413 -96,200	-51%	-$1.48M	0.02%	566
2020 Q2	$3.38M	Buy	+188,613	New	+$2.84M	0.04%	393

Martingale Asset Management's TBIO Position: Q3 2021 in Review

Martingale Asset Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 9,706 shares — an estimated $268K sold.

Martingale Asset Management first reported a position in TBIO in Q2 2020 and held it in 4 quarters. The position peaked at $3.38M in Q2 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

Martingale Asset Management reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Martingale Asset Management sold 9,706 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $268K.
Martingale Asset Management first reported a position in Translate Bio, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
Martingale Asset Management's Translate Bio, Inc. Common Stock position peaked at $3.38M in Q2 2020.
0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Martingale Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.